Proteins and Peptides

28 Jun 2022 Xenpozyme® (olipudase alfa) approved by European Commission as first and only treatment for ASMD
28 Jun 2022 Nexviadyme® (avalglucosidase alfa) approved by European Commission as a potential new standard of care for the treatment of Pompe Disease
17 Jun 2022 Rhythm Pharmaceuticals Announces FDA Approval of IMCIVREE® (setmelanotide) for Use in Patients with Bardet-Biedl Syndrome
15 Jun 2022 Clovis Oncology Highlights Phase 1 Data from Ongoing Clinical Studies of Targeted Radiotherapy Candidate FAP-2286 at SNMMI Annual Meeting
13 Jun 2022 Sogroya® data show potential as once-weekly treatment in children living with growth hormone deficiency
11 Jun 2022 Galderma Announces Positive Results in Two Phase III Studies for a Novel Liquid Formulation botulinumtoxinA (RelabotulinumtoxinA) for the Treatment of Glabellar Lines (frown) and Lateral Canthal Lines (crow’s Feet)
10 Jun 2022 Amytrx Therapeutic's AMTX-100 CF3 Moves to Phase II Clinical Trial for Atopic Dermatitis
08 Jun 2022 Innovent Announces Phase 2 study of Mazdutide(IBI362) in Chinese Participants with Overweight or Obesity Met Primary and All Key Secondary Endpoints
03 Jun 2022 Novo Nordisk achieves primary objectives of Onwards 1 and 6 trials with once-weekly insulin icodec demonstrating superior reduction in HbA1c vs insulin glargine U100 in Onwards 1
02 Jun 2022 ReAlta Life Sciences, Inc. Doses First Patient in Phase 1b Inhaled-LPS Challenge Clinical Trial to Support Development of RLS-0071 in Severe Asthma
30 May 2022 Amneal Achieves Third U.S. Biosimilar Approval with FYLNETRA™ (pegfilgrastim-pbbk)
27 May 2022 Data from SOTIO’s Phase 1/1b AURELIO-03 Trial of SOT101 Demonstrate Clinical Benefit in Patients with Solid Tumors
21 May 2022 BridgeBio Pharma Affiliate Phoenix Tissue Repair Announces Positive Results from Phase 2 Trial of PTR-01, a Protein Replacement Therapy for the Treatment of Recessive Dystrophic Epidermolysis Bullosa (RDEB)
20 May 2022 Aileron Therapeutics Announces First Patients Treated in Phase 1b Trial of ALRN-6924 in Patients with p53-Mutated Neoadjuvant Breast Cancer
14 May 2022 FDA approves Lilly's Mounjaro™ (tirzepatide) injection, the first and only GIP and GLP-1 receptor agonist for the treatment of adults with type 2 diabetes
10 May 2022 Synthetic Biologics Reports Positive Safety Data on SYN-020 Intestinal Alkaline Phosphatase Phase 1 Multiple Ascending Dose Clinical Trial
09 May 2022 selectION, Inc. Advances Lead Program for Treatment of T Cell Mediated Autoimmune Diseases to Clinical Development
04 May 2022 Topline Data for Dazodalibep (HZN-4920) Meets Primary Endpoint in Rheumatoid Arthritis
03 May 2022 Affibody, ACELYRIN, and Inmagene Bio Announce Positive Results from Global Phase 2 Trial of Izokibep in Patients with Psoriatic Arthritis
02 May 2022 Myovant Sciences Announces European Commission Approval for ORGOVYX® (relugolix) for the Treatment of Advanced Hormone-Sensitive Prostate Cancer
01 May 2022 Once-weekly insulin icodec demonstrates superior reduction in HbA1c vs insulin degludec in people with type 2 diabetes in ONWARDS 2 phase 3a trial
01 May 2022 Lilly's tirzepatide delivered up to 22.5% weight loss in adults with obesity or overweight in SURMOUNT-1
27 Apr 2022 Molecular Partners to Regain Global Rights for MP0310 from Amgen
26 Apr 2022 Protagonist Therapeutics Announces Topline Data from Phase 2 IDEAL Study of PN-943 in Ulcerative Colitis
24 Apr 2022 Nektar and Collaborators Present Preclinical Data on NKTR-255, a Novel IL-15 Receptor Agonist, in combination with CAR Cell Therapies at the 2022 Tandem Meetings | Transplantation & Cellular Therapy Meetings of ASTCT™ and CIBMTR®

La Merie Biologics

FREE Weekly News Bulletin

Sign Up

2021 Sales ofAntibodies & Proteins

New Product Alert

For La Merie Publishing

Sign Up